AAV Vector Gene Transfer with Sugar Medium

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current recombinant adeno-associated virus (rAAV) vectors require high vector genome copies for effective gene expression, leading to inefficient infection and the need for large quantities, which is inefficient and costly.

Innovation Solution

A composition comprising a recombinant virus vector, such as an rAAV vector, combined with a sugar at a higher concentration (at least 40 mM) in an aqueous medium, enhances gene transfer efficiency into target cells like hepatocytes and nerve cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high vector genome copies (10^4 vg or more per cell) are used for effective gene expression, then gene expression efficiency is improved, but the amount of vector required increases significantly

Engineering Contradiction:
Improvegene expression efficiencyVSAvoidamount of vector required
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The invention changes the chemical composition parameters of the delivery medium by adding sugars (glucose, fructose, sucrose, or maltose) at concentrations of 10 mM or more. This parameter change in the medium composition enhances rAAV vector infection efficiency, allowing effective gene expression with lower vector genome copies, thereby reducing the quantity of vector required while maintaining reliable gene expression

Inventive Principle:
Principle #35Parameter changes

2Reliability

If high vector genome copies are used to achieve effective gene expression, then gene transfer effectiveness is improved, but purification complexity and cost increase

Engineering Contradiction:
Improvegene transfer effectivenessVSAvoidpurification process complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

By modifying the delivery medium composition to include sugars at 10 mM or higher concentrations, the invention improves rAAV infection efficiency at the cellular level. This enhances gene transfer effectiveness using lower vector doses, which indirectly simplifies purification requirements and reduces the scale of purification operations needed, thereby reducing overall process complexity and cost

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS12188040B2Method for enhancing gene expression using AAV vector
Publication Date: 2025.01.07 GENE THERAPY RES INSTION CO LTD
  • US12188040B2 patent drawing
  • US12188040B2 patent drawing
  • US12188040B2 patent drawing

AI summary

The present invention relates to a composition for gene transfer comprising a recombinant virus vector and provides a composition for gene transfer which improves the efficiency of gene transfer using a virus vector. Specifically, the present invention provides a composition for gene transfer, which comprises a recombinant virus vector comprising a gene of interest for expression and a sugar at a concentration of at least 40 mM. The virus vector is preferably an adeno-associated virus vector. By using the composition of the present invention, the efficiency of gene transfer using a virus vector can be improved by about 50 times or more.